Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: The omegAD study

Journal of Lipid Research

Volumn 56, Issue 3, 2015, Pages 674-681

  Wang, Xiuzhe ^a,d   Hjorth, Erik ^a   Vedin, Inger ^b   Eriksdotter, Maria ^a   Freund Levi, Yvonne ^a   Wahlund, Lars Olof ^a   Cederholm, Tommy ^c   Palmblad, Jan ^b   Schultzberg, Marianne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid ; Clinical trials; Docosahexaenoic acid; Fatty acid; Fish oil; Inflammation; Lipoxin; Nutrition; Peripheral blood mononuclear cell; Resolvin

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID; FATTY ACID DERIVATIVE; ICOSAPENTAENOIC ACID; LIPOXIN A; PLACEBO; PREALBUMIN; RESOLVIN D1; SPECIALIZED PRORESOLVING MEDIATOR; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (10-40); AUTACOID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; COGNITION; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUPPLEMENTATION; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; METABOLISM; MONONUCLEAR CELL; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CELLS, CULTURED; COGNITION; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; MALE; PEPTIDE FRAGMENTS;

EID: 84925345642     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P055418     Document Type: Article

References (57)

1. Griffin, W. S., L. C. Stanley, C. Ling, L. White, V. MacLeod, L. J. Perrot, C. L. White III, and C. Araoz. 1989. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 86 : 7611-7615.
2. Araujo, D. M., and P. A. Lapchak. 1994. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience. 61 : 745-754.
3. Rao, J. S., S. I. Rapoport, and H. W. Kim. 2011. Altered neuroinflammatory, arachidonic acid cascade and synaptic markers in postmortem Alzheimer's disease brain. Transl. Psychiatry. 1: e31.
4. Galimberti, D., E. Venturelli, C. Fenoglio, I. Guidi, C. Villa, L. Bergamaschini, F. Cortini, D. Scalabrini, P. Baron, C. Vergani, et al. 2008. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. J. Neurol. 255: 539-544.
5. Angelopoulos, P., H. Agouridaki, H. Vaiopoulos, E. Siskou, K. Doutsou, V. Costa, and S. I. Baloyiannis. 2008. Cytokines in Alzheimer's disease and vascular dementia. Int. J. Neurosci. 118: 1659-1672.
6. Bermejo, P., S. Martin-Aragon, J. Benedi, C. Susin, E. Felici, P. Gil, J. M. Ribera, and A. M. Villar. 2008. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol. Lett. 117: 198-202.
7. Zuliani, G., M. Cavalieri, M. Galvani, A. Passaro, M. R. Munari, C. Bosi, A. Zurlo, and R. Fellin. 2008. Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia. J. Neurol. Sci. 272 : 164-170.
8. McGeer, P. L., and E. G. McGeer. 2007. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging. 28 : 639-647.
9. Trepanier, C. H., and N. W. Milgram. 2010. Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy? J. Alzheimers Dis. 21 : 1089-1099.
10. Rangel-Huerta, O. D., C. M. Aguilera, M. D. Mesa, and A. Gil. 2012. Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials. Br. J. Nutr. 107 (Suppl. 2): S159-S170.
11. Serhan, C. N. 2014. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 510: 92-101.
12. Lukiw, W. J., J. G. Cui, V. L. Marcheselli, M. Bodker, A. Botkjaer, K. Gotlinger, C. N. Serhan, and N. G. Bazan. 2005. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 115: 2774-2783.
13. Wang, X., M. Zhu, E. Hjorth, V. Cortés-Toro, H. Eyjolfsdottir, C. Graff, I. Nennesmo, J. Palmblad, M. Eriksdotter, K. Sambamurti, et al. 2015. Resolution of inflammation is altered in Alzheimer's disease. Alzheimers Dement. 11: 40-50.
14. Zhao, Y., F. Calon, C. Julien, J. W. Winkler, N. A. Petasis, W. J. Lukiw, and N. G. Bazan. 2011. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR-γ-mediated mechanisms in Alzheimer's disease models. PLoS ONE. 6: e15816.
15. Wang, X., E. Puerta, A. Cedazo-Minguez, E. Hjorth, and M. Schultzberg. 2015. Insufficient resolution response in the hippocampus of a senescence-accelerated mouse model - SAMP8. J. Mol. Neurosci. 55 : 396-405.
16. Zhu, M., X. Wang, M. Schultzberg, and E. Hjorth. 2015. Differential regulation of resolution in inflammation induced by amyloid-β42 and lipopolysaccharides in human microglia. J. Alzheimers Dis. 43: 1237-1250.
17. Medeiros, R., M. Kitazawa, G. F. Passos, D. Baglietto-Vargas, D. Cheng, D. H. Cribbs, and F. M. LaFerla. 2013. Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am. J. Pathol. 182: 1780-1789.
18. 4 signaling reduces Alzheimer's disease-like pathology in the 3xTg-AD mouse model. J. Alzheimers Dis. 43 : 893-903.
19. Freund-Levi, Y., M. Eriksdotter-Jönhagen, T. Cederholm, H. Basun, G. Faxen-Irving, A. Garlind, I. Vedin, B. Vessby, L. O. Wahlund, and J. Palmblad. 2006. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 63: 1402-1408.
20. Togo, T., H. Akiyama, E. Iseki, H. Kondo, K. Ikeda, M. Kato, T. Oda, K. Tsuchiya, and K. Kosaka. 2002. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J. Neuroimmunol. 124: 83-92.
21. Malm, T. M., M. Koistinaho, M. Parepalo, T. Vatanen, A. Ooka, S. Karlsson, and J. Koistinaho. 2005. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis. 18: 134-142.
22. Stalder, A. K., F. Ermini, L. Bondolfi, W. Krenger, G. J. Burbach, T. Deller, J. Coomaraswamy, M. Staufenbiel, R. Landmann, and M. Jucker. 2005. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J. Neurosci. 25: 11125-11132.
23. Simard, A. R., D. Soulet, G. Gowing, J. P. Julien, and S. Rivest. 2006. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 49 : 489-502.
24. Grathwohl, S. A., R. E. Kalin, T. Bolmont, S. Prokop, G. Winkelmann, S. A. Kaeser, J. Odenthal, R. Radde, T. Eldh, S. Gandy, et al. 2009. Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia. Nat. Neurosci. 12 : 1361-1363.
25. Michaud, J. P., M. A. Bellavance, P. Prefontaine, and S. Rivest. 2013. Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid β. Cell Reports. 5: 646-653.
26. Cao, C., G. W. Arendash, A. Dickson, M. B. Mamcarz, X. Lin, and D. W. A. Ethell. 2009. β-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol. Dis. 34: 63-70.
27. Gabelle, A., S. Schraen, L-A. Gutierrez, C. Pays, O. Rouaud, L. Buée, J. Touchon, C. Helmer, J-C. Lambert, and C. Berr. Plasma β-amyloid 40 levels are positively associated with mortality risks in the elderly. Alzheimers Dement. Epub ahead of print. July 8, 2014; doi: 10.1016/j.jalz.2014.04.515.
28. Speciale, L., E. Calabrese, M. Saresella, C. Tinelli, C. Mariani, L. Sanvito, R. Longhi, and P. Ferrante. 2007. Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol. Aging. 28: 1163-1169.
29. Vedin, I., T. Cederholm, Y. Freund Levi, H. Basun, A. Garlind, G. Faxen Irving, M. Eriksdotter Jönhagen, B. Vessby, L. O. Wahlund, and J. Palmblad. 2008. Effects of docosahexaenoic acid-rich omega-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am. J. Clin. Nutr. 87: 1616-1622.
30. Boberg, M., L. B. Croon, I. B. Gustafsson, and B. Vessby. 1985. Platelet fatty acid composition in relation to fatty acid composition in plasma and to serum lipoprotein lipids in healthy subjects with special reference to the linoleic acid pathway. Clin. Sci. 68: 581-587.
31. Faxén-Irving, G., Y. Freund-Levi, M. Eriksdotter-Jönhagen, H. Basun, E. Hjorth, J. Palmblad, I. Vedin, T. Cederholm, and L. O. Wahlund. 2013. Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. J. Alzheimers Dis. 36 : 1-6.
32. Lorenzo, A., and B. A. Yankner. 1994. β-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA. 91 : 12243-12247.
33. Mazur-Kolecka, B., and J. Frackowiak. 2006. Neprilysin protects human neuronal progenitor cells against impaired development caused by amyloid-β peptide. Brain Res. 1124 : 10-18.
34. Mazur-Kolecka, B., A. Golabek, K. Nowicki, M. Flory, and J. Frackowiak. 2006. Amyloid-β impairs development of neuronal progenitor cells by oxidative mechanisms. Neurobiol. Aging. 27: 1181-1192.
35. Lam, F. C., R. Liu, P. Lu, A. B. Shapiro, J. M. Renoir, F. J. Sharom, and P. B. Reiner. 2001. β-Amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76: 1121-1128.
36. Tew, D. J., S. P. Bottomley, D. P. Smith, G. D. Ciccotosto, J. Babon, M. G. Hinds, C. L. Masters, R. Cappai, and K. J. Barnham. 2008. Stabilization of neurotoxic soluble β-sheet-rich conformations of the Alzheimer's disease amyloid- β peptide. Biophys. J. 94: 2752-2766.
37. Vedin, I., T. Cederholm, Y. Freund-Levi, H. Basun, E. Hjorth, G. Faxén Irving, M. Eriksdotter-Jönhagen, M. Schultzberg, L. O. Wahlund, and J. Palmblad. 2010. Reduced prostaglandin F2{alpha} release from blood mononuclear leukocytes after oral supplementation of {omega}3 fatty acids: the OmegAD study. J. Lipid Res. 51: 1179-1185.
38. Cipollina, C., S. R. Salvatore, M. F. Muldoon, B. A. Freeman, and F. J. Schopfer. 2014. Generation and dietary modulation of antiinfl ammatory electrophilic omega-3 fatty acid derivatives. PLoS ONE. 9: e94836.
39. Mølvig, J., F. Pociot, H. Worsaae, L. D. Wogensen, L. Baek, P. Christensen, T. Mandrup-Poulsen, K. Andersen, P. Madsen, J. Dyerberg, et al. 1991. Dietary supplementation with omega-3-polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-1β content but not monokine secretion in healthy and insulin-dependent diabetic individuals. Scand. J. Immunol. 34: 399-410.
40. Schubert, R., R. Kitz, C. Beermann, M. A. Rose, P. C. Baer, S. Zielen, and H. Boehles. 2007. Influence of low-dose polyunsaturated fatty acids supplementation on the inflammatory response of healthy adults. Nutrition. 23 : 724-730.
41. Kelley, D. S., P. C. Taylor, G. J. Nelson, P. C. Schmidt, A. Ferretti, K. L. Erickson, R. Yu, R. K. Chandra, and B. E. Mackey. 1999. Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men. Lipids. 34: 317-324.
42. Amtul, Z., M. Uhrig, L. Wang, R. F. Rozmahel, and K. Beyreuther. 2012. Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: structural insight. Neurobiol. Aging. 33: 831.e21 - 831.e31.
43. Joshi, Y. B., A. Di Meco, and D. Pratico. 2014. Modulation of amyloid-β production by leukotriene B4 via the γ-secretase pathway. J. Alzheimers Dis. 38 : 503-506.
44. Levy, B. D., C. B. Clish, B. Schmidt, K. Gronert, and C. N. Serhan. 2001. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2: 612-619.
45. Itariu, B. K., M. Zeyda, E. E. Hochbrugger, A. Neuhofer, G. Prager, K. Schindler, A. Bohdjalian, D. Mascher, S. Vangala, M. Schranz, et al. 2012. Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am. J. Clin. Nutr. 96: 1137-1149.
46. Yaqoob, P., H. S. Pala, M. Cortina-Borja, E. A. Newsholme, and P. C. Calder. 2000. Encapsulated fish oil enriched in α-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions. Eur. J. Clin. Invest. 30 : 260-274.
47. Tan, Z. S., A. S. Beiser, R. S. Vasan, R. Roubenoff, C. A. Dinarello, T. B. Harris, E. J. Benjamin, R. Au, D. P. Kiel, P. A. Wolf, et al. 2007. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 68 : 1902-1908.
48. Shirahama, T., M. Skinner, P. Westermark, A. Rubinow, A. S. Cohen, A. Brun, and T. L. Kemper. 1982. Senile cerebral amyloid. Prealbumin as a common constituent in the neuritic plaque, in the neurofibrillary tangle, and in the microangiopathic lesion. Am. J. Pathol. 107 : 41-50.
49. Schwarzman, A. L., L. Gregori, M. P. Vitek, S. Lyubski, W. J. Strittmatter, J. J. Enghilde, R. Bhasin, J. Silverman, K. H. Weisgraber, P. K. Coyle, et al. 1994. Transthyretin sequesters amyloid β protein and prevents amyloid formation. Proc. Natl. Acad. Sci. USA. 91 : 8368-8372.
50. Stein, T. D., and J. A. Johnson. 2002. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J. Neurosci. 22 : 7380-7388.
51. Carro, E., J. L. Trejo, T. Gomez-Isla, D. LeRoith, and I. Torres-Aleman. 2002. Serum insulin-like growth factor I regulates brain amyloid-β levels. Nat. Med. 8: 1390-1397.
52. Choi, S. H., S. N. Leight, V. M. Lee, T. Li, P. C. Wong, J. A. Johnson, M. J. Saraiva, and S. S. Sisodia. 2007. Accelerated Aβ deposition in APPswe/PS1δE9 mice with hemizygous deletions of TTR (transthyretin). J. Neurosci. 27: 7006-7010.
53. Buxbaum, J. N., Z. Ye, N. Reixach, L. Friske, C. Levy, P. Das, T. Golde, E. Masliah, A. R. Roberts, and T. Bartfai. 2008. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Aβ toxicity. Proc. Natl. Acad. Sci. USA. 105: 2681-2686.
54. Costa, R., F. Ferreira-da-Silva, M. J. Saraiva, and I. Cardoso. 2008. Transthyretin protects against Aβ peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. PLoS ONE. 3 : e2899.
55. Wu, J., A. Wang, Z. Min, Y. Xiong, Q. Yan, J. Zhang, J. Xu, and S. Zhang. 2011. Lipoxin A4 inhibits the production of proinfl ammatory cytokines induced by β-amyloid in vitro and in vivo. Biochem. Biophys. Res. Commun. 408 : 382-387.
56. Mizwicki, M. T., G. Liu, M. Fiala, L. Magpantay, J. Sayre, A. Siani, M. Mahanian, R. Weitzman, E. Hayden, M. J. Rosenthal, et al. 2013. 1 α, 25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients. J. Alzheimers Dis. 34 : 155-170.
57. Hjorth, E., M. Zhu, V. C. Toro, I. Vedin, J. Palmblad, T. Cederholm, Y. Freund-Levi, G. Faxen-Irving, L. O. Wahlund, H. Basun, et al. 2013. Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid- β42 by human microglia and decrease inflammatory markers. J. Alzheimers Dis. 35 : 697-713.